IntegenX Strengthens Rapid Human DNA Identification Commercialization Team With Key Market Development Leader
Published: Jan 09, 2012
PLEASANTON, CA--(Marketwire - January 09, 2012) - IntegenX Inc., the leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA room temperature stability and storage products, today announced the appointment of Bob Barrett as Vice President of Strategy and Business Development for Human Identity Products (HID). Mr. Barrett will drive the strategy for introducing the RapidHIT™ 200 sample-to-profile HID system, and will develop the business relationships and plans for follow-on HID products.
Mr. Barrett has more than 25 years experience leading the successful commercialization of valuable novel products for diagnostics, biotechnology, and applied markets in the life sciences. His knowledge and expertise in applied markets and HID technologies is expected to accelerate the growth and widespread expansion of IntegenX HID solutions in defense, law enforcement, and applied markets. He has held senior executive positions at leading companies, most recently as Vice President of Global Marketing Molecular Diagnostics at QIAGEN. Prior to QIAGEN, Mr. Barrett was Vice President/General Manager of the Applied Markets Division at Applied Biosystems, where he played a key role in the development of the HID business. He also served as Vice President of Global Marketing at Roche Molecular Systems and as Vice President of Commercial Operations (Diagnostics) at Chiron Corporation.
"Recruiting a proven leader boosts our depth and breadth of talent to capture the emerging rapid HID market and to drive IntegenX technologies into new markets. Bob has a keen ability to identify, select, and develop strategies for the HID and applied markets as well as build teams to execute those plans," said Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX. "He has excellent capabilities to focus on developing and executing global commercial strategies for the RapidHIT 200."
"IntegenX is uniquely positioned to capitalize on the widespread adoption of rapid human DNA identification technologies by the public safety and defense communities," said Mr. Barrett. "IntegenX's RapidHIT system will provide local law enforcement the ability to secure fast positive identification of criminals and will give homeland security and military forces around the globe new tools to identify persons of interest."
About IntegenX Inc.
IntegenX, headquartered in Pleasanton, CA, is a privately-held company that leads the emerging field of rapid human DNA identification. IntegenX technology platforms are the result of integration of advanced fluidics and robotic capabilities to produce sample-to-answer products for DNA-based human identity testing and forensics, next generation sequencing, biodefense, and molecular diagnostics applications. The company's expertise and intellectual property includes its patented MOVe™ valve technology as well as a portfolio of patented DNA and RNA reagents including GenTegra™ for stabilization and storage of purified DNA and RNA, GenPlate® for storage of blood samples, and patent-pending PrepX™ reagent kits for next generation sequencing library preparation. For more information, please visit www.integenx.com.
Howard D. Goldstein
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588